News for SAP SE (SAP)

European companies including ASML Holding NV, Airbus SE and Mistral AI have called on the European Union to suspend the implementation of its landmark artificial intelligence regulation for two years because they say it puts the continent’s AI ambitions at risk.

3 themes stood out in CEOs’ minds in Q2 2025: Tariffs, possibility of recession, and agentic AI.

SAP SE (NYSE:SAP) is one of the 12 stocks that will make you rich in 10 years. On June 23, SAP Taulia, a subsidiary of SAP SE, announced a partnership with PayMate, a business-to-business (B2B) payment solutions provider. According to the agreement, PayMate’s payment infrastructure has been made available to SAP Taulia’s customers. The integration […]

Berenberg analyst Nay Soe Naing has elevated the price target for SAP (SAP) from EUR 280 to EUR 289 while maintaining a Buy rating. This decision highlights the

One of the most read (and recommended) books on investing is Benjamin Graham’s The Intelligent Investor. Among many others, long-term investing is a foundational theme in the book.

Insights from the Second Quarter 2025 N-PORT Filing iShares MSCI ACWI ex U.S. ETF (Trades, Portfolio) recently submitted its N-PORT filing for the second quart

SAP SE (NYSE:SAP) is one of the 12 best cryptocurrency and blockchain stocks to buy.

We came across a bullish thesis on RELX PLC (RELX) on FluentInQuality’s Substack. In this article, we will summarize the bulls’ thesis on RELX. RELX PLC (RELX)’s share was trading at $52.97 as of 10th June. RELX ’s trailing and forward P/E were 38.02 and 29.94 respectively according to Yahoo Finance. RELX Plc (REL) has quietly transformed […]

SAP SE (NYSE:SAP) is one of the 11 must-buy AI stocks analysts are betting on. On June 16, Piper Sandler analyst Brent Bracelin initiated coverage with an ‘Overweight’ rating EUR 350 price target. The overweight rating underscores expectations for the company’s earnings growth, followed by significant expansion in the valuation multiples. The analyst reiterated the […]

SAP SE (NYSE:SAP) is one of the 10 software stocks analysts are upgrading. On June 13, research firm Warburg Research upped the price objective on the company’s stock from €275 to €295, while maintaining a “Buy” rating. The firm’s analyst, Andreas Wolf, sees further cloud growth and margin improvements, which led to the increase in […]

Vodafone Group Plc has appointed Pilar López as its new chief financial officer following the departure of Luka Mucic, who announced he was leaving last month.

Whoever controls artificial intelligence could have an advantage, possibly reshaping the geopolitical balance of power.

Alibaba Group Holding Limited (NYSE:BABA) is one of the 13 Most Undervalued Retail Stocks to Buy Right Now. Alibaba Group Holding Limited’s (NYSE:BABA) earnings for the March quarter and fiscal year 2025 showed a 7% year-over-year growth in revenue to RMB 236.454 billion ($32.584 billion). Income from operations experienced a notable 93% year-over-year growth, reaching […]

An analyst from Piper Sandler, Brent Bracelin, has initiated coverage of SAP (SAP) with an Overweight rating, setting a price target at EUR 350. According to th

Piper Sandler has commenced coverage on SAP (SAP) with a positive outlook, assigning it an Overweight rating and setting a price target of EUR 350. This move hi

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and SAP SE.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with ...

(Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments. Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said. CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at 1.04 billion euros ($1.2 billion), while BioNTech shares were down 2% by 1237 GMT.

There are various ways to collect unethical competitive intelligence, but ultimately, they all morally compromise the people who participate in them.